DE4012894A1 - Compsns. contg. carnitine and fish oil - for preventing and treating fat metabolism disorders, esp. hyperlipidaemia - Google Patents

Compsns. contg. carnitine and fish oil - for preventing and treating fat metabolism disorders, esp. hyperlipidaemia

Info

Publication number
DE4012894A1
DE4012894A1 DE19904012894 DE4012894A DE4012894A1 DE 4012894 A1 DE4012894 A1 DE 4012894A1 DE 19904012894 DE19904012894 DE 19904012894 DE 4012894 A DE4012894 A DE 4012894A DE 4012894 A1 DE4012894 A1 DE 4012894A1
Authority
DE
Germany
Prior art keywords
fish oil
carnitine
contg
fish
fat metabolism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19904012894
Other languages
German (de)
Other versions
DE4012894C2 (en
Inventor
Halvor Dr Jaeger
Joachim Dr Kappler
Werner Dr Gielsdorf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REDINOMEDICA AG, 33649 BIELEFELD, DE
Original Assignee
L A B & Co GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L A B & Co GmbH filed Critical L A B & Co GmbH
Priority to DE19904012894 priority Critical patent/DE4012894C2/en
Publication of DE4012894A1 publication Critical patent/DE4012894A1/en
Application granted granted Critical
Publication of DE4012894C2 publication Critical patent/DE4012894C2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs

Abstract

Fish oil is obtd. from cold water fish and contains 18-50 wt% omega-3 type polyunsatd. fatty acids. Specifically claimed is a compsn. contg. 10-30 wt% eicosapentaenoic acid and 7-20 wt% docosahexaenoic acid. USE/ADVANTAGE - Carnitine-fish oil compsn. sharply reduces levels of serum lipids and lipoproteins. Carnitine (formerly vitamin BT) is transport protein for acyl gps. in fat metabolism. Total dose of active ingredients is 1-10 g/day.

Description

Die Erfindung betrifft ein pharmazeutisches Mittel zur Behandlung von Störungen des Fettstoffwechsels, insbeson­ dere der Hyperlipidämie, auf der Grundlage von Fischöl und Carnitin.The invention relates to a pharmaceutical agent for Treatment of disorders of fat metabolism, in particular that of hyperlipidemia, based on fish oil and carnitine.

Arteriosklerose ist nach Herzkrankheiten und Krebserkran­ kungen eine der Haupttodesursachen bei Menschen. Ein Risikofaktor für die Erkrankung an Arteriosklerose ist eine erhöhte Menge an Serumlipiden und Lipoproteinen, so daß eine Senkung der Serumlipid- und Lipoproteinspiegel für die Therapie wichtig ist.Atherosclerosis is after heart disease and cancer crane one of the main causes of death in humans. A Risk factor for arteriosclerosis disease an increased amount of serum lipids and lipoproteins, causing a decrease in serum lipid and lipoprotein levels is important for therapy.

Als Lipidsenker kommen neben den seit langem bekannten Chemotherapeutika in neuerer Zeit Produkte zur Anwendung, die sich in natürlichen Materialien finden. In diesem Zusammenhang sind in erster Linie ungesättigte Fettsäuren zu nennen.As lipid-lowering agents come alongside those that have been known for a long time Chemotherapy drugs more recently products for use, that are found in natural materials. In this The connection is primarily unsaturated fatty acids to call.

Die EP-A-8 61 16 933 beschreibt ein pharmazeutisches Präparat zur Behandlung von Störungen des Fettstoffwech­ sels, das Knoblauchextrakt und Fischöl enthält. Mit diesem Präparat sollen bei Dosierungen von 2 bis 4 g pro Tag vorteilhafte Ergebnisse erzielt werden.EP-A-8 61 16 933 describes a pharmaceutical Preparation for the treatment of disorders of the fat metabolism sels, which contains garlic extract and fish oil. With this The preparation should be used at doses of 2 to 4 g per day advantageous results can be achieved.

Carnitin-(4-Amino-3-hydroxybuttersäuretrimethylbetain), das früher als Vitamin BT bezeichnet wurde, kommt in allen Geweben, insbesondere der quergestreiften Muskula­ tur vor. Es ist als Transportprotein von Acylgruppen am Fettstoffwechsel beteiligt. Carnitine (4-amino-3-hydroxybutyric acid trimethylbetaine), formerly known as vitamin B T , occurs in all tissues, especially the striated muscles. As a transport protein of acyl groups, it is involved in fat metabolism.

Überraschenderweise wurde nun gefunden, daß eine Kombination von Carnitin und Fischöl in der Lage ist, den Serumlipid- und Lipoproteinspiegel stark zu senken.Surprisingly, it has now been found that a combination of carnitine and fish oil is able to reduce the serum lipid and greatly lower lipoprotein levels.

Gegenstand der vorliegenden Erfindung ist daher ein pharmazeutisches Mittel, das Fischöl und Carnitin enthält. Dieses Mittel ist zur Behandlung von Störungen des Fett­ stoffwechsels und insbesondere der Hyperlipidämie brauch­ bar.The subject of the present invention is therefore a pharmaceutical agent containing fish oil and carnitine. This remedy is used to treat fat disorders metabolism and especially hyperlipidemia bar.

Fischöl, das erfindungsgemäß zur Anwendung kommen kann, ist in der EP-A-8 61 16 933 beschrieben. Auf diese Publi­ kation wird hiermit in vollem Umfang Bezug genommen.Fish oil, which can be used according to the invention, is described in EP-A-8 61 16 933. On this publi cation is hereby fully referred to.

Fischöl hat einen hohen Gehalt an C18 bis C22-Fettsäuren, insbesondere vom Omega-3-Typ. Dies gilt insbesondere für das Fischöl von Kaltwasserfischen.Fish oil has a high content of C 18 to C 22 fatty acids, especially of the omega-3 type. This applies in particular to the fish oil from cold water fish.

Vorzugsweise verwendet man daher Fischöl von Kaltwasser­ fischen, insbesondere Fischöl aus dem Fleisch von Lachsen, Heringen, Salmen, Forellen, Sardellen, Makrelen und/oder Sardinen sowie Lebertran, insbesondere von Dorschen.Fish oil from cold water is therefore preferably used fish, especially fish oil from salmon meat, Herring, salmon, trout, anchovy, mackerel and / or Sardines and cod liver oil, especially from cod.

Besonders bevorzugt enthält das Fischöl 15 bis 50 Gew.-%, insbesondere 20 bis 30 Gew.-% hochungesättigte Fettsäuren vom Omega-3-Typ. Zu derartigen Fettsäuren zählen Eico­ sapenteinsäure und Docosahexaensäure. Vorzugsweise setzt man Fischöl ein, das 10 bis 30 Gew.-%, insbesondere 15 bis 20 Gew.-% Eicosapentaensäure und 7 bis 20 Gew.-%, insbesondere 10 bis 15 Gew.-% Docosahexaensäure enthält.The fish oil particularly preferably contains 15 to 50 % by weight, in particular 20 to 30% by weight, of highly unsaturated fatty acids of the omega-3 type. Such fatty acids include eico sapentic acid and docosahexaenoic acid. Fish oil is preferably used which contains 10 to 30% by weight, in particular 15 to 20% by weight, of eicosapentaenoic acid and 7 to 20% by weight, in particular 10 to 15% by weight of docosahexaenoic acid.

Das Carnitin kann auch in Form eines pharmazeutisch ver­ träglichen Salzes, z. B. als Hydrochlorid, eingesetzt werden. Das Carnitin kommt vorzugweise als L-Carnitin zur Anwendung. The carnitine can also be in the form of a pharmaceutical ver inert salt, e.g. B. be used as hydrochloride. The carnitine is preferably used as L-carnitine.  

Das Verhältnis von Fischöl zu Carnitin liegt im allgemeinen im Bereich von 1 : 2 bis 10 : 1, vorzugsweise im Bereich von 1 : 1 bis 5 : 1.The ratio of fish oil to carnitine is generally in the range of 1: 2 to 10: 1, preferably in the range of 1: 1 to 5: 1.

Das erfindungsgemäße Mittel wird insbesondere oral verab­ reicht. Geeignete Darreichungsformen sind Kapseln, Lösun­ gen, Dispersionen etc. Vorzugsweise wird das Mittel als Kapsel (Weich- oder Hartgelatine) verabreicht, die 500 bis 1000 mg, insbesondere 600 bis 800 mg, Fischöl und 200 bis 400 mg, insbesondere 200 bis 300 mg, Carnitin enthält. Das Mittel kann auch in zwei Teilen vorliegen, wobei die beiden Komponenten voneinander getrennt gleich­ zeitig oder nacheinander verabreicht werden können.The agent according to the invention is administered orally in particular enough. Suitable dosage forms are capsules, solutions conditions, dispersions etc. The agent is preferably used as Capsule (soft or hard gelatin) administered, the 500th up to 1000 mg, especially 600 to 800 mg, fish oil and 200 to 400 mg, especially 200 to 300 mg, carnitine contains. The agent can also be in two parts, the two components being the same separately from each other can be administered early or sequentially.

Die Herstellung der erfindungsgemäßen Mittel erfolgt in üblicher Weise durch Zusammengeben oder getrennte Formulierung der beiden Komponenten, gegebenenfalls unter Verwendung üblicher Zusätze und Hilfsstoffe.The agents according to the invention are produced in the usual way by combining or separate Formulation of the two components, if necessary under Use of common additives and auxiliary substances.

Die Dosierung des erfindungsgemäßen Mittels liegt im allgemeinen im Bereich von 1 bis 10 Gramm pro Tag bei Erwachsenen, wobei Fischöl und Carnitin in den genannten Mengenanteilen vorliegen.The dosage of the agent according to the invention is generally in the range of 1 to 10 grams per day Adults, with fish oil and carnitine in the above Quantities are available.

Das nachfolgende Beispiel erläutert die Erfindung.The following example explains the invention.

Beispielexample

Jeweils 200 mg Carnitin werden mit jeweils 400, 500 und 600 mg Heringsöl, Sardinenöl und Lachsöl in eine Weich­ gelatinekapsel gefüllt.Each 200 mg of carnitine with 400, 500 and 600 mg of herring oil, sardine oil and salmon oil in a soft filled gelatin capsule.

Claims (7)

1. Pharmazeutisches Mittel, enthaltend Fischöl und Carnitin oder ein pharmazeutisch verträgliches Salz davon.1. Pharmaceutical composition containing fish oil and Carnitine or a pharmaceutically acceptable salt thereof. 2. Pharmazeutisches Mittel nach Anspruch 1, dadurch gekennzeichnet, daß das Fischöl von Kaltwasserfischen stammt.2. Pharmaceutical composition according to claim 1, characterized in that the fish oil comes from cold water fish. 3. Pharmazeutisches Mittel nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß das Fischöl 18 bis 50 Gew.-% hochungesättigte Fettsäuren vom Omega-3-Typ enthält.3. Pharmaceutical composition according to claim 1 or 2, characterized in that the fish oil 18 to 50% by weight of highly unsaturated omega-3 type fatty acids contains. 4. Pharmazeutisches Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß das Fischöl 10 bis 30 Gew.-% Eicosapentaensäure und 7 bis 20 Gew.-% Docosahexaensäure enthält.4. Pharmaceutical agent according to one of the preceding Claims, characterized in that the fish oil 10 to 30% by weight eicosapentaenoic acid and 7 to Contains 20% by weight docosahexaenoic acid. 5. Pharmazeutisches Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß das Verhältnis von Fischöl zu Carnitin im Bereich von 1 : 2 bis 10 : 1 liegt.5. Pharmaceutical agent according to one of the preceding Claims, characterized in that the ratio from fish oil to carnitine in the range of 1: 2 to 10: 1 lies. 6. Pharmazeutisches Mittel nach einem der vorhergehenden Ansprüche in Form einer Dosiseinheit, insbesondere in Form einer Kapsel, die 500 bis 1000 mg Fischöl und 200 bis 300 mg Carnitin enthält. 6. Pharmaceutical agent according to one of the preceding Claims in the form of a dose unit, in particular in the form of a capsule containing 500 to 1000 mg of fish oil and contains 200 to 300 mg of carnitine.   7. Verwendung von Fischöl und Carnitin wie in einem der Ansprüche 1 bis 6 definiert, zur präventiven oder therapeutischen Behandlung von Störungen des Fettstoff­ wechsels, insbesondere der Hyperlipidämie.7. Use fish oil and carnitine as in one of the Claims 1 to 6 defined, for preventive or therapeutic treatment of disorders of the fatty substance alternating, especially hyperlipidemia.
DE19904012894 1990-04-23 1990-04-23 Pharmaceutical agent for the treatment of disorders of the fat metabolism Expired - Lifetime DE4012894C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19904012894 DE4012894C2 (en) 1990-04-23 1990-04-23 Pharmaceutical agent for the treatment of disorders of the fat metabolism

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19904012894 DE4012894C2 (en) 1990-04-23 1990-04-23 Pharmaceutical agent for the treatment of disorders of the fat metabolism

Publications (2)

Publication Number Publication Date
DE4012894A1 true DE4012894A1 (en) 1991-10-24
DE4012894C2 DE4012894C2 (en) 1998-11-12

Family

ID=6404903

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19904012894 Expired - Lifetime DE4012894C2 (en) 1990-04-23 1990-04-23 Pharmaceutical agent for the treatment of disorders of the fat metabolism

Country Status (1)

Country Link
DE (1) DE4012894C2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19503993A1 (en) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Enteral product contg n-3-fatty acid or deriv and medium chain length tri:glyceride
EP0780124A1 (en) * 1995-12-21 1997-06-25 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Pharmaceutical composition comprising L-carnitine or an alkanoyl L-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and the treatment of lipid metabolism disorders
DE10214005A1 (en) * 2002-03-27 2003-10-09 Volker Bartz Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids
ES2208131A1 (en) * 2002-03-27 2004-06-01 Volker Bartz Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3721137A1 (en) * 1987-06-26 1989-01-05 Dietl Hans Fat emulsion for intravenous use
DE3726299A1 (en) * 1987-06-26 1989-02-23 Dietl Hans Fat emulsion for intravenous use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3721137A1 (en) * 1987-06-26 1989-01-05 Dietl Hans Fat emulsion for intravenous use
DE3726299A1 (en) * 1987-06-26 1989-02-23 Dietl Hans Fat emulsion for intravenous use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE-Z: WEBER, P.C. *
SCHACKY, v.C: HochunggesättigteFettsäuren vom w-3-Typ, Nr. 1/2, 126.Jg., 1986, S.4-7 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19503993A1 (en) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Enteral product contg n-3-fatty acid or deriv and medium chain length tri:glyceride
EP0780124A1 (en) * 1995-12-21 1997-06-25 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Pharmaceutical composition comprising L-carnitine or an alkanoyl L-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and the treatment of lipid metabolism disorders
DE10214005A1 (en) * 2002-03-27 2003-10-09 Volker Bartz Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids
ES2208131A1 (en) * 2002-03-27 2004-06-01 Volker Bartz Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids

Also Published As

Publication number Publication date
DE4012894C2 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
DE3926658C2 (en) Fatty acid composition
DE4133694C2 (en) Use of an emulsion with polyunsaturated fatty acids for i.v. administration for the treatment of skin diseases
DE2905979C2 (en) Use of acetylated, distilled monoglycerides for the treatment of lipid metabolic disorders in humans
DE3409793A1 (en) LIQUID EMULSION FOR TRANSFUSION
DE19855426A1 (en) Agents for the therapy and prophylaxis of rheumatic-arthritic diseases and for the prophylaxis of cardiovascular diseases
EP0584159B1 (en) Nutrient preparation
WO2010057804A1 (en) Fat emulsion for artificially feeding seriously ill intensive care patients
DE3323585A1 (en) COMPOSITION TO REDUCE SEBUM SECRETION
US5516801A (en) Fatty acid treatment for ectopic calcium deposition
EP1660097B1 (en) Physiologically active composition based on phosphatidylserine
DE4012894C2 (en) Pharmaceutical agent for the treatment of disorders of the fat metabolism
EP0273407B1 (en) Medicine for improving the specific properties of blood
DE10214005A1 (en) Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids
EP0232501A1 (en) Pharmaceutical preparation for the treatment of lipid metabolism disorders (hyperlipoproteinemia)
EP0585027A1 (en) Use of fatty acids for treating abnormal tissue calcification
DE60124516T2 (en) COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID
EP1965791B1 (en) Novel compositions against alkyl-acyl-gpc, the derivatives and products thereof
DE60316362T2 (en) USE OF HYDROXYLIC ACID AND RELATED COMPOUNDS AS FUNCTIONAL FOOD ADDITIVES
DE202008003509U1 (en) Pharmaceutical composition for the prophylaxis and treatment of arteriosclerosis, as well as for pain relief and anti-inflammatory
DE19956400A1 (en) Cholesterol-lowering cardioprotective and vasoprotective composition comprises conjugated linoleic acids and omega-3 fatty acids
DE2033629C3 (en) Orally administrable agent for lowering the serum lipid level in humans
DE4042437A1 (en) Topical compsn. for treating burns - contg. omega-3-fatty acid esp. eicosa-penta:enoic acid as fish oil component, providing rapid healing
DE3910760C2 (en)
DE2401449A1 (en) PHARMACEUTICAL COMPOSITION FOR THE RELIEF OF SKIN PROLIFERATIONAL DISEASES
EP1147769A2 (en) Use of polyunsaturated fatty acids, especially omega-3-fatty acids, for the treatment of enuresis and incontinence

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: GIELSDORF, WERNER, DR., 89346 BIBERTAL, DE

D2 Grant after examination
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: REDINOMEDICA AG, 80538 MUENCHEN, DE

8327 Change in the person/name/address of the patent owner

Owner name: REDINOMEDICA AG, 33649 BIELEFELD, DE

8327 Change in the person/name/address of the patent owner

Owner name: SFS INTERNATIONAL LTD., CLONMEL, TIPPERARY, IE